about
Firing up the nature/nurture controversy: bioethics and genetic determinismHuntington's disease: the past, present, and future search for disease modifiers.Huntington's diseaseGenetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesisRole of Rab GTPases in membrane traffic and cell physiologyUnilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.Visualising disease progression on multiple variables with vector plots and path plotsMotor-Language Coupling in Huntington's Disease Families.Familial conformational diseases and dementias.Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.Validity of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD).Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells.Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application.Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington diseaseVerbal episodic memory declines prior to diagnosis in Huntington's disease.Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease?Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.Cell line profiling to improve monoclonal antibody production.Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseasesMaintenance of chaperone-mediated autophagy activity in cultured cells expressing mutant huntingtin.Adenosine as a neuroprotectant: therapeutic perspectives.P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes?Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment.Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation.Folding of polyglutamine chains.Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
P2860
Q24681950-40C6B67B-5212-42B3-9556-63474F1DBBE7Q26830039-2C715EB3-0FFD-4EC2-8371-91F0FF99B01AQ28365461-9911BCFB-F9FC-41FA-B133-871B9B288DE8Q28507529-63A812C9-9677-4225-B807-E9552EDEA3DAQ29616548-320A7B18-C944-4076-BDA0-F80341C1B276Q31118947-E9466E0B-B529-4AA3-9E3E-53FE402B05CAQ33454017-0398E392-9230-43E0-9E53-2D29D9F8D170Q33743709-073062A5-C653-4219-982A-A081F24A2B02Q34138249-89172498-AFBA-429C-A877-0421CBDB3728Q34443430-DE1B62A7-690C-4B5E-A68F-EAA6B33D0CD0Q35836823-2538C94A-0712-4D24-96F3-459697339DF7Q36519737-5B6B751E-C120-4E0F-8240-732D981BA8A1Q36565588-ADA6F4BD-2B33-4743-87BB-42EA2898F3D3Q36606399-B20ABD47-7373-4899-A8DC-D66F4407BC4EQ36813683-9838C3D9-753F-49FD-8BDA-7A6EF215D8F3Q36943511-46645514-7776-41F8-A7C5-8C5716D5F237Q37039456-8C36481B-1BA0-463A-B503-29C354A74D1DQ37731940-FD1324EE-4FA9-4751-8A1E-BB4D46AC9B8EQ38103448-B460E43B-58BB-4788-A970-3C5A03189D87Q38408049-B9B2D056-6583-4974-B86B-C88B65E8C953Q39061545-EC37A515-22E5-4156-8050-571BD265165CQ39310077-4EEDE072-13A9-4F8D-841A-4C9F64821E66Q40512075-B9458D7F-F926-41E4-96E8-772F47AF522FQ40657295-2AE68C29-54FC-4305-804D-06F133F84C62Q41108776-621163C1-270E-40CF-A774-71C97B8DC801Q44662096-F92A0957-693E-4569-A125-B47C94F90EF2Q45288978-9E8216B2-E96E-4CBF-9CF2-BA17B4B9611BQ45300776-BCC405F6-8592-494D-958C-9615D3A605B3Q45306368-BE7C4CEA-4E20-4FE8-BF8D-2A809D9D5356Q47206201-7DB0E49B-429C-41F5-9870-174B4C6488F0Q58780496-88780A1F-8413-4463-8DB4-CE85C3C6A12C
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The molecular biology of Huntington's disease.
@ast
The molecular biology of Huntington's disease.
@en
type
label
The molecular biology of Huntington's disease.
@ast
The molecular biology of Huntington's disease.
@en
prefLabel
The molecular biology of Huntington's disease.
@ast
The molecular biology of Huntington's disease.
@en
P2093
P1476
The molecular biology of Huntington's disease.
@en
P2093
Carmichael J
Rubinsztein DC
Wyttenbach A
P356
10.1017/S0033291799002871
P407
P577
2001-01-01T00:00:00Z